- Home
- HURA vs MIST Comparison
HURA vs MIST Comparison
Compare HURA & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HURA | MIST |
|---|---|---|
| Founded | 2009 | 2003 |
| Country | United States | Canada |
| Employees | 22 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.5M | 176.3M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | HURA | MIST |
|---|---|---|
| Price | $2.07 | $1.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $9.50 | $8.00 |
| AVG Volume (30 Days) | 327.9K | ★ 1.1M |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $2,915.14 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $1.00 |
| 52 Week High | $3.90 | $3.06 |
Technical Indicators
Market Signals| Indicator | HURA | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 37.88 | 26.25 |
| Support Level | $1.82 | $1.00 |
| Resistance Level | $2.20 | $1.42 |
| Average True Range (ATR) | 0.14 | 0.06 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 1.32 | 3.00 |
Price Performance
Historical ComparisonAbout HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).